Made Scientific recently held a ribbon-cutting ceremony to commemorate the grand opening of its new 60,000 sq. ft. GMP manufacturing facility and headquarters in Princeton, New Jersey.
The opening marks the completion of a $12 million initial investment in facility upgrades, equipment, and business system digitization, strengthening Made Scientific's position in the rapidly growing cell therapy sector and commitment to building long-term manufacturing capacity to support the next generation of cell therapies globally. A second phase of expansion has already been announced, and the company is expected to grow its workforce with more than 100 additional skilled professionals, strengthening the company's regional presence and industry influence.
"Today is more than a ribbon cutting. It is a clear signal of our commitment to this incredible industry and to this region," said Syed T. Husain, Chairman and CEO of Made Scientific. "This facility is a testament to our dedication to supporting the next generation of cell therapy innovators for clinical-to-commercial manufacturing, all under one roof. With a globally compliant infrastructure, high-throughput GMP capacity, and a world-class team built for precision and speed, we are here to help our partners bring transformative therapies to patients with confidence and efficiency."
The Princeton facility includes five (5) ISO 7 / Grade B cleanrooms, in-house quality control labs, and dedicated process and analytical development capabilities. It also incorporates advanced digital infrastructure, including Oracle NetSuite® for Enterprise Resource Planning (ERP), Veeva Systems for Quality Management (QMS), Autolomous AutoloMATE® for Electronic Batch Records and Manufacturing Execution (MES), and LabVantage® for Laboratory Information Management (LIMS), ensuring end-to-end program visibility and operational rigor.
As part of its broader expansion, the event highlighted Made Scientific's recent announcement of an additional 12,000 square-foot build-out of GMP manufacturing cleanroom space, which will meet U.S. FDA and EU Annex 1 compliance standards and include high-throughput and automated manufacturing technologies. Once fully operational, the expansion will increase capacity by up to 2,000 additional batches per year to support late-phase and commercial programs.